- About Us
- Services & Solutions
- Technologies
- Discovery
- Reagent Materials Generation
- Monoclonal Antibody Discovery
- Bispecific & Multispecific Antibody Generation
- Lead Optimization
- In Vitro Lead Characterization
- In Vivo Lead Characterization
- Other Molecular Modalities
- IND Filing Support
- Protein Sciences
- Protein Production
- Protein Analytics
- Bioinformatics
- Protein Sciences
- Mammalian
- Microbial
- mRNA
- Viral Vaccines
- WuXi XDC – Bioconjugation
- Testing
- Sustainability
- Careers
- Investors
- News & Resources
WuXi Biologics
Offering End-to-End Solutions
- About Us
About Us - Services & SolutionsAbout Us
- SustainabilityAbout Us
- CareersAbout Us
- InvestorsAbout Us
- News & ResourcesAbout Us
Scientific Poster Download
PepTalk 2023
Accelerating Early Drug Discovery Process with Vanilla Antibody Production using 777 Platform
Gaozhan Zhang, Deyang Zeng, Dawei Zhang, Mengjie Lu, Jiansheng Wu
WuXi Biologics, NO.240 Hedan Road, Pudong New District, Shanghai, China
| The assessment of binding affinity, biological properties, and critical developability parameters for thousands of candidates in early antibody drug discovery process often requires small amounts of purified materials (< 1g). To support our clients and to overcome the challenges associates with protein production, WuXi Biologics has established one HTP antibody production platform “777”, representing 7 days for gene synthesis, 7 days for protein expression, and 7 days for purification and QC. |  |
Notice:
You are leaving WuXi Biologics Website, after which our Privacy Notice will not apply. Please keep it in mind the protection of your privacy. Are you willing to proceed?